Interleukin-6 (IL-6) is a key cytokine involved in both acute and chronic inflammation. It is produced at the site of inflammation and plays a central role in the acute phase response, which includes the production of acute phase proteins. IL-6, in combination with its soluble receptor sIL-6Rα, facilitates the transition from acute to chronic inflammation by altering the type of leukocyte infiltrate, shifting from neutrophils to monocytes and macrophages. IL-6 also stimulates T- and B-cell activity, promoting chronic inflammatory responses. In acute inflammation, IL-6 is a stimulator of acute phase proteins and helps regulate the immune response. However, in chronic inflammation, IL-6 becomes pro-inflammatory, contributing to the persistence of inflammation by promoting mononuclear cell accumulation, angioproliferation, and anti-apoptotic effects on T cells. IL-6 is involved in the development of chronic inflammatory diseases such as rheumatoid arthritis, colitis, and experimental autoimmune encephalomyelitis. IL-6 signaling through sIL-6Rα controls leukocyte infiltration and is crucial for the transition from acute to chronic inflammation. The complex of IL-6 and sIL-6Rα activates endothelial cells, leading to the secretion of chemokines and adhesion molecules that facilitate monocyte recruitment. This process is essential for resolving inflammation and initiating immune responses. In chronic inflammation, IL-6 levels are elevated, contributing to disease progression. IL-6 is involved in the development of immune responses, including B-cell differentiation, immunoglobulin secretion, and T-cell activation. Targeting IL-6 and its signaling pathways has shown promise in the prevention and treatment of chronic inflammatory diseases. IL-6 has dual roles in inflammation, acting as an anti-inflammatory cytokine in acute responses and a pro-inflammatory cytokine in chronic inflammation. Blocking IL-6 and its signaling pathways is a potential therapeutic approach for chronic inflammatory diseases. The study highlights the importance of IL-6 in the regulation of inflammation and its potential as a therapeutic target.Interleukin-6 (IL-6) is a key cytokine involved in both acute and chronic inflammation. It is produced at the site of inflammation and plays a central role in the acute phase response, which includes the production of acute phase proteins. IL-6, in combination with its soluble receptor sIL-6Rα, facilitates the transition from acute to chronic inflammation by altering the type of leukocyte infiltrate, shifting from neutrophils to monocytes and macrophages. IL-6 also stimulates T- and B-cell activity, promoting chronic inflammatory responses. In acute inflammation, IL-6 is a stimulator of acute phase proteins and helps regulate the immune response. However, in chronic inflammation, IL-6 becomes pro-inflammatory, contributing to the persistence of inflammation by promoting mononuclear cell accumulation, angioproliferation, and anti-apoptotic effects on T cells. IL-6 is involved in the development of chronic inflammatory diseases such as rheumatoid arthritis, colitis, and experimental autoimmune encephalomyelitis. IL-6 signaling through sIL-6Rα controls leukocyte infiltration and is crucial for the transition from acute to chronic inflammation. The complex of IL-6 and sIL-6Rα activates endothelial cells, leading to the secretion of chemokines and adhesion molecules that facilitate monocyte recruitment. This process is essential for resolving inflammation and initiating immune responses. In chronic inflammation, IL-6 levels are elevated, contributing to disease progression. IL-6 is involved in the development of immune responses, including B-cell differentiation, immunoglobulin secretion, and T-cell activation. Targeting IL-6 and its signaling pathways has shown promise in the prevention and treatment of chronic inflammatory diseases. IL-6 has dual roles in inflammation, acting as an anti-inflammatory cytokine in acute responses and a pro-inflammatory cytokine in chronic inflammation. Blocking IL-6 and its signaling pathways is a potential therapeutic approach for chronic inflammatory diseases. The study highlights the importance of IL-6 in the regulation of inflammation and its potential as a therapeutic target.